7 Key Budget 2026 Health Moves That Will Shape India’s Future | Health

Biopharma SHAKTI commits Rs. 10,000 crore to scale biologics manufacturing, translational research, and supply chains over five years, a strategic bet on biosimilars, advanced therapies, and domestic capacity. The fund aims to foster industry-academia incubators, incentives for advanced production, and a stronger export orientation. If executed, the scheme could reduce import dependence, lower therapy costs, and attract global investment into India’s next-generation drug industry. This measure requires clear timelines and state-level coordination.